Abreva

Abreva is a drug used for topical treatment for recurrent herpes simplex labialis episodes (episodes of cold sores or fever blisters). A saturated 22-carbon aliphatic alcohol, docosanol exhibits antiviral activity against many lipid enveloped viruses including herpes simplex virus (HSV). Abreva inhibits fusion between the plasma membrane and the herpes simplex virus (HSV) envelope, thereby preventing viral entry into cells and subsequent viral replication.

Abreva - Pharmacology:

Abreva works by inhibiting fusion between the human cell plasma membrane and the herpes simplex virus (HSV) envelope, thereby preventing viral entry into cells and subsequent viral replication. Unlike other cold-sore antivirals, docosanol does not act directly on the virus, and as such it is unlikely it will produce drug resistant mutants of HSV.

Abreva mini report

Abreva NDA
NDA - A product marketed under an approved New Drug Application
Abreva HUMAN OTC DRUG
HUMAN OTC DRUG
Start - Stop data
START DATA:
2010-Mar-19
Start - Stop data
STOP DATA
not occurred

Generic name, Overdose, Half Life Abreva, Food Interactions, Chemical, etc..

Abreva see also